Compare TAOP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | BOLT |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 10.5M |
| IPO Year | 2012 | 2021 |
| Metric | TAOP | BOLT |
|---|---|---|
| Price | $1.30 | $4.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 5.8K | ★ 24.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.25 | $0.26 |
| 52 Week High | $8.78 | $7.35 |
| Indicator | TAOP | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 50.23 |
| Support Level | $1.20 | $4.33 |
| Resistance Level | $1.59 | $5.05 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 70.61 | 43.48 |
Taoping Inc is a provider of cloud-based technology solutions, smart city IoT platforms, digital advertising delivery systems, and internet-based information distribution systems in China. The company has three reportable segments. The Cloud-based Technology segment includes cloud-based products, high-end data storage servers, advertising services, and customized software solutions for private sector customers. The Traditional Information Technology segment includes project-based technology products and services sold to the public sector, including Geographic Information Systems, Digital Public Security Technology, and Digital Hospital Information Systems. The Smart Elevator segment provides elevator sales, installation, maintenance, renovation, and cloud-based maintenance services.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.